Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

Segurança e Eficácia do Aripiprazol no Tratamento de Manutenção a Longo Prazo de Pacientes Pediátricos com Irritabilidade Associada ao Transtorno Autista

The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

215

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alabama
      • Dothan, Alabama, Estados Unidos, 36303
        • Harmonex Neuroscience Research, Inc
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85006
        • Southwest Autism Research And Resource Center
    • California
      • Costa Mesa, California, Estados Unidos, 92626
        • Clinical Innovations, Inc.
      • Glendale, California, Estados Unidos, 91206
        • Behavioral Research Specialists, Llc
      • Palo Alto, California, Estados Unidos, 94306
        • Abbey Neuropsychology Clinic
      • San Francisco, California, Estados Unidos, 94143
        • Ucsf - Lppi
      • Stanford, California, Estados Unidos, 94305
        • Stanford University School Of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • Children'S National Medical Center
    • Florida
      • Gainesville, Florida, Estados Unidos, 32607
        • Sarkis Clinical Trials
      • Hialeah, Florida, Estados Unidos, 33012
        • Palm Springs Research Institute
      • Maitland, Florida, Estados Unidos, 32751
        • Florida Clinical Research Center, Llc
      • Miami, Florida, Estados Unidos, 33155
        • Miami Children'S Hospital
      • Tampa, Florida, Estados Unidos, 33613
        • University Of South Florida
    • Georgia
      • Smyrna, Georgia, Estados Unidos, 30080
        • Institute For Behavioral Medicine, Llc
    • Idaho
      • Coeur d'Alene, Idaho, Estados Unidos, 83814
        • Kootenai Behavioral Health Center
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40202
        • Kosair Charities Pediatric Clinical Research Unit
    • Louisiana
      • Shreveport, Louisiana, Estados Unidos, 71103
        • Lsu Health Sciences Center
    • Massachusetts
      • Newton, Massachusetts, Estados Unidos, 02459
        • Neurocare, Inc.
    • Michigan
      • Bloomfield Hills, Michigan, Estados Unidos, 48302
        • Neurobehavioral Medicine Group
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Center For Psychiatry And Behavioral Medicine, Inc
    • New Jersey
      • Gibbsboro, New Jersey, Estados Unidos, 08026
        • Clinical Research Center Of New Jersey
      • Toms River, New Jersey, Estados Unidos, 08755
        • Children'S Specialized Hosp
    • New York
      • Stony Brook, New York, Estados Unidos, 11794
        • Stony Brook University School Of Medicine
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27517
        • Unc Chapel Hill
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Case Medical Center
      • Cleveland, Ohio, Estados Unidos, 44104
        • Cleveland Clinic
      • Columbus, Ohio, Estados Unidos, 43210
        • The Ohio State University Nisonger Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73116
        • Cutting Edge Research Group
      • Oklahoma City, Oklahoma, Estados Unidos, 73117
        • Ou Physician'S Child Study Center
      • Tulsa, Oklahoma, Estados Unidos, 74104
        • Tulsa Clinical Research, Llc
    • Oregon
      • Gresham, Oregon, Estados Unidos, 97030
        • Cyn3rgy Research
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19124
        • Drexel University College Of Medicine
      • Pittsburgh, Pennsylvania, Estados Unidos, 15203
        • Western Psychiatric Institute And Clinic
    • Tennessee
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Holston Medical Group
    • Texas
      • DeSoto, Texas, Estados Unidos, 75115
        • Insite Clinical Research
    • Utah
      • Clinton, Utah, Estados Unidos, 84015
        • Ericksen Research And Development
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23510
        • Childrens Specialty Gr., Pllc
      • Richmond, Virginia, Estados Unidos, 23298
        • Virginia Treatment Center For Children

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

6 anos a 17 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Key Inclusion Criteria:

  • Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
  • Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
  • Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
  • Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
  • An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
  • Mental age of at least 24 months

Key Exclusion Criteria:

  • Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
  • Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
  • Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
  • Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
  • History of neuroleptic malignant syndrome
  • At significant risk for suicide based on history or routine psychiatric status examination
  • A seizure within the past year
  • History of severe head trauma or stroke
  • History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
  • Weight lower than 15 kg
  • Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
  • History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
  • Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo

Tablets, oral, 0 mg, once daily, 16 weeks

Experimental: Aripiprazol

Tablets, oral, 2-15 mg, once daily, 13-42 weeks

Outros nomes:
  • Abilify
  • BMS-337039

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Patients Relapsing by Week 16
Prazo: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.

From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
Prazo: From Baseline (end of Phase 1) to Week 16 of Phase 2

ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
Prazo: From Baseline (end of Phase 1) to Week 16 of Phase 2

CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
Prazo: Up to 26 weeks

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Up to 26 weeks

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
Prazo: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

7 de março de 2011

Conclusão Primária (Real)

20 de junho de 2012

Conclusão do estudo (Real)

20 de junho de 2012

Datas de inscrição no estudo

Enviado pela primeira vez

22 de outubro de 2010

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de outubro de 2010

Primeira postagem (Estimado)

25 de outubro de 2010

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever